Stopping tirzepatide is the part of the GLP-1 story that doesn’t fit into a before-and-after photo. The clearest evidence comes from SURMOUNT-4 (Aronne et al., JAMA, 2024), a randomized withdrawal trial funded by Eli Lilly. Stage one: 783 adults with obesity or overweight, without diabetes, received tirzepatide for 36 weeks. The 670 participants who reached randomization had lost an average of 20.9% of their starting body weight. Stage two: Participants were randomized to continue tirzepatide or switch to placebo for another 52 weeks. The results: Continued tirzepatide: another 5.5% weight reduction. Switched to placebo: 14% weight regain. 89.5% of participants continuing treatment maintained at least 80% of their initial weight loss. Only 16.6% of the placebo group maintained that same threshold. Here’s what people overlook. At week 88, the placebo group was still approximately 9.9% below its original weight. So no, everyone didn’t simply regain everything. But substantial weight regain was common. What the trial didn’t establish: Whether gradual tapering reduces rebound weight gain. How resistance training and dietary interventions might influence weight maintenance. How much of the regained weight consisted of fat versus lean tissue. The takeaway? Tirzepatide isn’t failing when weight returns after discontinuation. Obesity is a chronic condition, and the biological mechanisms driving appetite and weight regulation don’t necessarily disappear because someone lost weight. These medications may be better understood as long-term metabolic therapies rather than temporary weight-loss interventions. That’s an important distinction when discussing expectations, treatment duration, and long-term outcomes. #Tirzepatide #GLP1 #MetabolicHealth #WeightLoss #ObesityResearch #Biohacking #ClinicalResearch